Anti-platelet aggregation

6-Hydroxykaempferol-3,6,7-triglucoside
Catalog No: CFN92521

6-Hydroxykaempferol 3,6,7-tri-O-glucoside and 6-hydroxykaempferol 3,6-di-O-glucoside can inhibit platelet aggregation induced by collagen, they also show weak inhibitory effects on the adenosine 5'-diphosphate (ADP)- induced platelet aggregation.

(+)-Pteryxin
Catalog No: CFN92559

(+)-Pteryxin has muscle-relaxant props, it also shows hepatoprotective and nitric oxide prodn. inhibitory activity.

Tetrahydroberberine
Catalog No: CFN90506

Tetrahydroberberine, with D(2) receptor antagonist and 5-HT(1A) receptor agonist properties, has significant potential as a therapeutic for treatment of FD; it has antidopaminergic effect, and other pharmacological action on the central nervous system. Tetrahydroberberine can inhibit the rabbit platelet aggregation.

Oxoglaucine
Catalog No: CFN90508

Oxoglaucine exerts immunomodulatory effect in vivo in a dose-dependent and protocol-dependent manner, it also exhibits significant antiplatelet aggregation activity against rabbit platelets induced by thrombin, arachidonic acid, collagen or platelet activating factor. Oxoglaucine and pachypodol are anti-picornavirus compounds, phosphatidylinositol 4-kinase III beta (PI4KB) as the direct target of them.

Ginsenoside Rk1
Catalog No: CFN92644

Ginsenoside Rk1, one of the main elements of Sung Ginseng, has been confirmed as a new endothelial barrier enhancer recently and has anti-cancer activity, the mechanism involves coordination between inhibition of telomerase activity and induction of apoptosis.